Approved for use through 07/31/2006. OMB 0651-0031

Approved for use through 07/31/2006, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE er the Paperwork <u>Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.</u>

Request For Continued Examination (RCE) Transmittal

Address to:
Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

ed to respond to a collection of informat	tion unless it contains a valid Q	MB control numb	er.
Application Number	09/738,742)
Filing Date	December 15,	2000	
First Named Inventor	Jason Hill	JUN	1 1004
Art Unit	1653		TA 180012900
Examiner Name	David Lukton	LUH VEN	9,9,50
Attorney Docket Number	C058)

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application.

Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

 Submission required under 37 CFR 1.114 Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s). 				
a. Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.				
i. Consider the arguments in the Appeal Brief or Rely Brief previously filed on				
li Other				
I. X Amendment/Reply iji. Information Disclosure Statement (IDS)				
ii. Affidavit(s)/ Declaration(s) iv. x Other Terminal Disclaimer				
2. Miscellaneous				
Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a a. period of months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)				
b. Other Months. (Period of suspension shall not exceed 3 months, Peer under 37 GFK 1.17() required)				
The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed. The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 50–1986 i. RCE fee required under 37 CFR 1.17(e) ii. Extension of time fee (37 CFR 1.136 and 1.17)				
i. X RCE fee required under 37 CFR 1.17(e)				
ii. Extension of time fee (37 CFR 1.136 and 1.17) iii. X Other Terminal Disclaimer Fee b. Check in the amount of \$enclosed				
iii. X Other <u>Terminal Disclaimer Fee</u>				
b. Check in the amount of \$enclosed				
c. Payment by credit card (Form PTO-2038 enclosed)				
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.				
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED				
Name (Print/Type) / Timothy J. Houkos Registration No. (Attomey/Agent) 41,716 Signature Date May 25, 2004				
Signature Date May 25, 2004 Date May 25, 2004 Date Date May 25, 2004 Date May 25, 2004 Date Date May 25, 2004 Date Date				
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop RCE, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.				
Name (Print/Type) Timothy Doparos				
Signature Date May 25, 2004 This collection of information is required by 37/CFR 1.114. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO				

This collection of information is required by 37CFR 1.114. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

he Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number RERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING REJECTION OVER A PENDING SECOND APPLICATION

Docket Number (Optional)

C058

In re Application of: Jason Hill et al.

Application No.: 09/738,742 Filed: December 15, 2000

For: NOVEL LIPOPEPTIDES AS ANTIBACTERIAL AGENTS

1 2004

The owner*, Cubist Pharmaceuticals, Inc., of 100 percent interest in the instant application hereby disclaim (except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 and 173 as shortened by any terminal disclaimer filed prior to the grant of any patent granted on pending second Application Number 09/739,535 filed on December 15, 2000, of any patent on the pending second application. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the second application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of any patent granted on the second application, as shortened by any terminal disclaimer filed prior to the patent grant, in the event that any such granted patent: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

Check either box 1 or 2 below, if appropriate.

		For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency,
	ш	etc.), the undersigned is empowered to act on behalf of the organization.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

The undersigned is an attorney or agent of record.

RECEIVED

JUN 0 1 2004

TECH CENTER 1600/2900

Date

Timothy J. Douros

Typed or printed name

781 860 8660

Telephone Number

Terminal disclaimer fee under 37 CFR 1,20(d) is included.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this statement. See MPEP § 324.

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

09738742

728/2004 DEMMANUI 00000008 501986